Non-addictive opioid painkillers are expected to be available
September 10, 2018 Source: Ministry of Science and Technology
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];On August 29th, Professor Mei-Chuan Ko of Wake Forest Medical College in the United States reported the development of the bifunctional NOP/MOP receptor agonist AT-121 in Science Translational Medicine, which has partial agonists for both NOP and MOP receptors. active.
Mu opioid peptide (MOP) receptor agonists are very effective in relieving severe pain and are currently the most effective and widely used analgesics, but related to their abuse, addiction and possible respiratory arrest. It has led to the global opioid crisis. There is therefore an urgent need to develop drugs that are effective in treating severe pain but are not addictive.
The results in non-human primates indicate that bifunctional NOP/MOP agonists have an appropriate balance of NOP and MOP agonist activity, providing a safe and dual therapeutic effect. AT-121 treatment did not cause side effects associated with opioids such as respiratory depression, abuse, hyperalgesia, and drug dependence.
Medton Medical , https://www.medtonmedical.com